Citation APA
Colleoni, M. A., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Hitre, E., Graas, M.-P., Simoncini, E., Kamby, C., Thompson, A. M., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Di Lauro, V., Gombos, A., Ruhstaller, T., Burstein, H., Ribi, K., Bernhard, J., Viale, G., Maibach, R., Rabaglio-Poretti, M., Gelber, R. D., Coates, A. A., Di Leo, A., Regan, M., Goldhirsch, A., & SOLE Investigators, (2018). Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 19(1), 127-138. doi:10.1016/S1470-2045(17)30715-5
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/290445